Search - tctmd.com

Displaying 41 - 51 of 51

Sort: Relevancy | Date

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

Presentation

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

February 11, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

Podcast TCTMD Talking Points

DES for Femoropopliteal Disease: IMPERIAL

January 09, 2019

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Video

» On Record

On Record: An Update on Paclitaxel-based Devices in PAD

October 21, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Kenneth Ouriel About LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

September 26, 2019

Advertisement

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

DES for Femoropopliteal Disease: IMPERIAL

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

On Record: An Update on Paclitaxel-based Devices in PAD

Dr. C. Michael Gibson Talks With Dr. Kenneth Ouriel About LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content